FindTrial
Sign In

Bifidobacterium BB-12 in the prevention of antibiotic-associated diarrhoea in critical ill patients:a randomised, double-blind, placebo-controlled trial

Bifidobacterium BB-12 in the prevention of antibiotic-associated diarrhoea in critical ill patients:a randomised, double-blind, placebo-controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-POR-15005944
Enrollment
Unknown
Registered
2015-01-30
Start date
2013-06-03
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

antiobiotic-associated diarrhea

Interventions

A:receive placebo identical in taste and appearance,3g/d,8d
B:receive probiotic supplement (containing 0.6*10^8 colony-forming units Bifidobacterium animalis subsp. lactis BB-12 per gram),3g/d,8d

Sponsors

Department of Clinical Nutrition,West china hospital, Sichuan university
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. adult patients age over 18 years; 2. days using antibiotics are not less than 4 day; 3. patients can use enteral nutrition; 4. signed informed consent.

Exclusion criteria

Exclusion criteria: 1. digestive diseases which lead to diarrhea easily, such as ulcerative colitis, gastrointestinal cancer or allergic gastrointestinal syndrome et al; 2. fecal incontinence; 3. pregnant women; 4. diarrhea 15 days before the trial; 5. severe immunosuppression; 6. taking over probiotics 15 days before the trial; 7. patients only use total parenteral nutrition.

Design outcomes

Primary

MeasureTime frame
the incidence of AAD;—

Secondary

MeasureTime frame
the number of days of diarrhea;—

Countries

China

Contacts

Public ContactWen Hu
wendyhu67@21cn.com+86 18980601164

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026